JMAT.L - Johnson Matthey Plc

LSE - LSE Delayed Price. Currency in GBp
-9.00 (-0.28%)
As of 10:52AM BST. Market open.
Stock chart is not supported by your current browser
Previous Close3,190.00
Bid3,184.00 x 6500
Ask3,184.00 x 5600
Day's Range3,161.00 - 3,190.00
52 Week Range2,574.00 - 3,783.00
Avg. Volume570,449
Market Cap6.11B
Beta (3Y Monthly)1.26
PE Ratio (TTM)14.82
Earnings DateN/A
Forward Dividend & Yield0.85 (2.69%)
Ex-Dividend Date2019-06-06
1y Target EstN/A
Press Releases
  • PR Newswire2 months ago

    Johnson Matthey introduces the Mining CRT diesel emission control systems for underground mining equipment.

     -- System improves mine health and safety by providing clean air for workers, with no impact on productivity.  -- More than 99% of particulates are destroyed, giving the best possible work environment. AUDUBON, Pa., April 30, 2019 /PRNewswire/ --Johnson Matthey (JMAT.L), a global leader in science that enables a cleaner and healthier world, introduces an advanced system to control emissions from diesel underground mining equipment for healthier work environments.

  • GlobeNewswire6 months ago

    Immunomedics and Johnson Matthey Announce Strategic Manufacturing Partnership

    Immunomedics, Inc., (IMMU) and Johnson Matthey (LSE: JMAT), today announced the companies have expanded their long-term master supply agreement under which Johnson Matthey will continue to scale the manufacturing of CL2A-SN-38, the drug-linker that is a key component of sacituzumab govitecan, Immunomedics’ lead antibody-drug conjugate currently under priority review by the FDA for accelerated approval as a treatment for patients with metastatic triple-negative breast cancer. This is part of Immunomedics' ongoing commitment to invest in and scale its global supply capacity with world-class partners in each component of its supply-chain.

  • We're sorry this is all we were able to find about this topic.